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PSEA Results
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• Biomarkers for stratification of patient subgroups for diagnosis, treatment selection, the measurement of response, etc. are a clinically unmet need in many disease indications • We developed a method that utilizes mass spectral data collected from patient serum samples in combination with a protein expression panel measuring 1129 proteins to create scores that probe biological processes underlying human cancer • Biological processes reported here include acute response (AR), complement system, and wound healing (WH) • We explored the behavior of the scores in NSCLC and ovarian cancer and the scores through the course of treatment • A tool that measures the activity of a complex biological process could be useful in deciding when an intervention is needed (screening), or for monitoring the effects during therapy
We would like to acknowledge F. Grossi and S. Kasimir-Bauer for allowing use of serum samples to evaluate a new method
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Application
• A score can be computed for any biological function from a mass spectrum acquired and processed using the same method • Datasets:
• NSCLC: development set (n=85) treated with erlotinib, validation set 1 (n=123) treated with chemotherapy, validation set 2 (n=60) treated with nivolumab; longitudinal samples collected at treatments cycles 4 (C4), 7 (C7), 9 (C9), and 11 (C11) • Ovarian (n=165) treated with adjuvant chemotherapy
• Deep MALDI 1 : Reproducible ultrasensitive high-throughput serum profiling
• Protein Set Enrichment Analysis 2,3 probes the underlying biological processes within human serum samples that may be related to disease • Protein expression values for the analysis set (n=49) were used to identify mass spectral features correlated with several biological functions
• Principal component analysis (PCA) was performed using the development set of 85 NSCLC pretreatment samples • 2 17 realizations of PCA, using 2/3 of the samples in each bag, were performed to ensure the result was not prone to a biased PCA solution • PSEA combined with PCA were used to create scores for several biological functions including acute response, complement, and wound healing • The scores are correlated with survival and applying a threshold could be used to stratify patients into high or low score groups • While preliminary, scores may be clinically useful to give a better understanding of the biological processes at work compared with single biomarker measurements before and through the course of therapy 
